Search Results

Imatinib mesylate

Imatinib mesylate is FDA approved to treat

Cytarabine

Cytarabine is FDA approved to prevent and treat leukemia that has spread to the meninges (the three membranes that cover the brain and spinal cord). It is also FDA approved for use with other drugs to treat acute myeloid leukemia, acute lymphoblastic leukemia and chronic myeloid leukemia. This medicine may cause a temporary loss of hair in some people. After treatment with cytarabine has ended, normal hair growth should return.

Liposomal cytarabine (DepoCyt®) is given by intrathecal injection. It is FDA approved to treat lymphoma that has spread to the meninges.

FDA Approves New Maintenance Treatment for AML

Some promising news to kick off Blood Cancer Awareness Month – on September 1, 2020, the U.S. Food and Drug Administration approved a new oral maintenance treatment for certain adult patients with acute myeloid leukemia (AML).

CC-486 (Onureg®) is now approved for the continued treatment of adult patients with AML who achieved first complete remission (CR) or CR with incomplete blood count recovery (Cri) following intensive induction chemotherapy and who are not able to undergo intensive curative therapy, such as hematopoietic stem cell transplant.

Targeting AML

 

Not for lack of trying, we’ve seen very little progress over the past 40 years in treating acute myeloid leukemia (AML), an aggressive and deadly blood cancer. But we’re finally starting to see the needle move and The Leukemia & Lymphoma Society (LLS) is playing a leading role in going on the offensive against the disease.

Panelists Discuss the AML Patient Experience

What is AML? What research is underway? And what resources are available to patients?

The Leukemia & Lymphoma Society recently joined up with Patient Power and the MDS Alliance to host an AML Awareness Day and answer those questions.

The April 21 webcast was moderated by Carol Preston, host of Patient Power, an online portal offering cancer information for both patients and professionals. Preston is also a chronic lymphocytic leukemia (CLL) survivor.

Blinatumomab

Blinatumomab is FDA approved for the treatment of adult and pediatric patients one month and older with: 

Strategic combinations to overcome therapeutic resistance and relapse in acute myeloid leukemia

Acute myeloid leukemia (AML) is the most fatal type of leukemia and has a high rate of relapse following current therapies. We have recently uncovered that RSPO3-LGR4 pathway is a key regulator of leukemia-initiating cell activity and is exclusively activated in relapsed and refractory AML. Our project aims to investigate the mechanistic link between the pathway activation and therapy resistance, and design combination therapies that would overcome resistance and improve the treatment of relapsed leukemia.

Diagnosed with a Blood Cancer? Important Questions You Might Not Think to Ask

What is my actual diagnosis? Find out your exact diagnosis. Ask your doctor to write down the exact name of your sub-type and take the paper with you. For example, knowing you have “a B-cell lymphoma” isn’t good enough. Follicular and diffuse large B-cell are both B-cell lymphomas but with very different prognoses and treatment plans. Leukemia also has different sub-types. Knowing your specific sub-type helps you understand what disease you are dealing with, how aggressive it is, and what to expect from treatment.

Investigational CLL Therapy to Get Priority Review by FDA

Marking another promising advance for the treatment of patients with chronic lymphocytic leukemia, including those with a rare subset of this blood cancer, the U.S. Food and Drug Administration (FDA) has granted priority review for an investigational compound that has shown positive results in a Phase II clinical trial.

Developing novel therapeutic approaches for classical and variant hairy cell leukemia

In this proposal, we have combined clinical and research expertise in HCL across Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, the University of Pennsylvania, and Yale University to develop newer targeted therapeutics for every stage and subtype of hairy cell leukemia.

Immunotherapy Study Funded by The Leukemia & Lymphoma Society Demonstrates Remarkable Results in Patients with Acute Lymphoblastic Leukemia

Leukemia Research Funded by The Leukemia & Lymphoma Society Gets Infusion of Support from Startup Biotechnology Company

Blood is life: How one teenager draws strength from her Native American heritage

Investigating and targeting the histone acetylation reader protein ENL in acute leukemias

Leukemia often results from aberrant gene expression caused by epigenetic alterations. Previously we discovered a novel histone acetylation reader domain in the ENL protein and demonstrated that this domain is essential for the survival of a wide range of acute leukemias, making it an attractive therapeutic target. We will develop specific inhibitors of ENL activity in acute leukemias and will use mouse models to define the role of ENL mutations identified in patients in leukemogenesis.

Families Fighting for Cancer Cures: Generation LLS

 

As an organization founded by a family for families, The Leukemia & Lymphoma Society (LLS) is celebrating 70 years of impact on generations of families, researchers and volunteers while looking to the future by redoubling its commitment to improve treatments and care for children with cancer.

Targeting the interplay between signaling and transcriptional dysfunction in myeloid leukemias

Our research program is focused on understanding the intersection between signaling and transcriptional dysfunction in myeloid leukemias. We leverage murine models, cell lines and human samples to uncover how biological context shapes the manifestation of oncogenic programs at the molecular level. Our long-term goal is to harness this knowledge to identify multipronged therapeutic strategies that improve outcomes for patients with myeloid malignancies.

SHP2 and BCL2 Inhibition in Acute Myeloid Leukemia

The goal of our work is to use a “bench to bedside and back” approach to develop new treatments for patients with relapsed/refractory AML. Through genetic analysis of patients who relapse or do not respond to standard and investigational treatments, we discover potential resistance mechanisms. In the lab, we test novel drugs and identify new drug targets that may address these resistance mechanisms when used in combination with other therapies. The overall goal of our research program is to improve treatment options and survival of patients with refractory AML.

Spotlight on Caregiving: Chronic Lymphocytic Leukemia (CLL)

Highlights in Therapy: Chronic Myeloid Leukemia (CML)

Acute Lymphoblastic Leukemia (ALL) In Children And Adults

Ask the Expert: Acute Myeloid Leukemia (AML)

Chronic Myeloid Leukemia: Know Your Options

LLS Applauds Significant Approval for Leukemia Patients

Burlington and The Leukemia and Lymphoma Surprise a Young Survivor